These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 35283215)

  • 1. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients.
    Toniutto P; Cussigh A; Cmet S; Bitetto D; Fornasiere E; Fumolo E; Fabris M; D'Aurizio F; Fabris C; Grillone L; Sartor A; Curcio F; Falleti E
    Liver Int; 2023 Feb; 43(2):452-461. PubMed ID: 35661561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
    J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
    Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
    Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
    Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
    Zecca E; Rizzi M; Tonello S; Matino E; Costanzo M; Rizzi E; Casciaro GF; Manfredi GF; Acquaviva A; Gagliardi I; Calzaducca E; Mallela VR; D'Onghia D; Minisini R; Bellan M; Castello LM; Gavelli F; Avanzi GC; Patrucco F; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Sola D; Sainaghi PP
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients.
    Toniutto P; Cussigh A; Cmet S; Fabris M; Curcio F; Bitetto D; Fornasiere E; Fumolo E; Falleti E
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study.
    Matsunami M; Suzuki T; Sugihara S; Toishi T; Nagaoka K; Fukuda J; Ohara M; Takanashi Y; Ochi A; Yashima J; Kuji H; Matsue K
    Transplant Proc; 2022; 54(6):1483-1488. PubMed ID: 35868872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers.
    Khalaileh A; Imam A; Jammal A; Hakimian D; Amer J; Shafrir A; Milgrom Y; Massarwa M; Hazou W; Khader M; Safadi R
    Hepatol Commun; 2023 Feb; 7(2):e0025. PubMed ID: 36724131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.
    Tomiyama T; Suzuki R; Harada N; Tamura T; Toshida K; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Takeishi K; Itoh S; Kobayashi N; Ito H; Yoshio S; Kanto T; Yoshizumi T; Fukuhara T
    Front Cell Infect Microbiol; 2023; 13():1197349. PubMed ID: 37260700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
    Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
    Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients.
    Miura M; Fukumoto M; Komatsu N; Shuto R; Harada H; Sasaki H
    Int J Urol; 2022 Dec; 29(12):1505-1510. PubMed ID: 36070502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.